|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, IL-17 obviously inhibits the antitumor effects of IFN-γ in hepatoma cells and, in turn, accelerates HCC development through upregulating the expression of the negative feedback regulator PIAS1 of the JAK/STAT1 pathway via enhancing activation of NF-κB.
|
31784083 |
2020 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway.
|
30780004 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Induction of p-STAT1 by IFN-α treatment effectively triggers the expression of interferon-stimulated genes (ISGs), but has moderate effect on HCC cell growth.
|
30456450 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TMUB1 expression was positively correlated with STAT1 in 132 HCC tissues, TMUB1 promoted the expression of STAT1, and suppressed the expression of CCND1 in HCC cells.
|
31827061 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we found that use of an adjuvant of fludarabine, a chemotherapeutic drug for chronic myeloid leukemia, increased the replication of Newcastle disease virus (NDV) by targeting signal transducer and activator of transcription 1 (STAT1), which led to enhanced oncolysis of hepatocellular carcinoma (HCC) cells.
|
31011625 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma.
|
30546827 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest a novel strategy of using resveratrol to enhance the response of HCC to IFN-α treatment through the SIRT/STAT1 pathway.
|
29762078 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results for the first time indicate that IFN-α treatment promotes oncogenic PVT1 expression in HCC cells, which interacts with STAT1 to inhibit IFN-α signaling, ultimately blocking IFN-α-induced cells apoptosis, suggesting that lncRNA PVT1 may be a potential target to improve IFN-α-mediated HCC immunotherapies.
|
29715456 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of eEF1A1 regulates G1-phase progression to promote HCC proliferation through the STAT1-cyclin D1 pathway.
|
29079187 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aflatoxin B<sub>1</sub> inhibits the type 1 interferon response pathway via STAT1 suggesting another mechanism of hepatocellular carcinoma.
|
28344639 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that aberrant proteolysis appeared to occur frequently during recurrence of HCC in several key signal transducers, including STAT1 and δ-catenin.
|
24967658 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study attempted to evaluate any possible association among TNF-α (-308G>A) and IFN-γ (+874T/A) genotypes, the spontaneous blood and mRNA levels and expression of their major signal transducers, namely STAT1 and NF-кB with hepatitis B virus-induced hepatocellular carcinoma (HCC) susceptibility in India.
|
24101445 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, signal transducer and activator of transcription 1 and phosphatase and tensin homolog were associated with early growth response protein 1 signaling in non-tumor lesions, which potentially promotes angiogenesis, fibrogenesis, and tumorigenesis in CH-C-related HCC.
|
23485556 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggest that STAT1 may inhibit HCC growth by regulating p53-related cell cycling and apoptosis.
|
23588992 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In human samples, 29 HCCs were resected, divided into two groups based on STAT1 activation in tumor and the clinical features were investigated.
|
22488367 |
2012 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among them, the expression profiles of MDR1, GAGE1, STAT1 and MAP7 were significantly associated with the expression of Pyk2 in clinical HCC samples.
|
22096562 |
2011 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrate for the first time that polymorphisms in the STAT1 gene are associated with HCC susceptibility.
|
20798561 |
2010 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we demonstrate that long-term (3-6 days) but not short-term (up to 1 day) IFN-gamma treatment of human hepatoma Hep3B cells attenuates IFN-alpha activation of STAT1 (signal transducers and activators of transcription factor 1), STAT2 and STAT3, but enhances IFN-gamma and interleukin 6 activation of STATs.
|
14690454 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among the HCCs, the mRNA expression levels of STAT1 and the downstream genes were higher in tumors without portal vein involvement than in more malignant HCCs with portal vein involvement.
|
15490234 |
2004 |